Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Chemotherapy as Neoadjuvant Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
ChiCTR2600126570Phase 2Not yet recruiting
- Sponsor
- Department of Oncology, Sixth Medical Center of PLA General Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Department of Oncology, Sixth Medical Center of PLA General Hospital. Primary endpoint: Major pathological response (MPR). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600126570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126570.